Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940 | Completed Phase 1 FDA Drug

• 1 other identifier: ENV-294-101
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 5

Brief Summary

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are:

• Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis?
• Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will:
• Take drug ENV-294 once every day for 28 days
• Visit the clinic weekly for 4 weeks for checkups and tests
• Keep a diary of their symptoms and when they took their study drug ENV-294

Conditions

Atopic Dermatitis (AD)

Outcome Measures

Primary Outcomes (18)

• To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis.

  Incidence and severity of adverse events, serious adverse events and adverse events leading to the discontinuation of treatment.

  From enrollment through treatment and the final study visit at approximately day 42.

• Incidence of abnormalities in clinical chemistry parameters as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant abnormalities in clinical chemistry parameters will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

  Baseline through end of study at approximately Day 42.

• To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis

  Incidence of clinically significant changes in physical exam findings after ENV-294 administration.

  From first dose through treatment and the final study visit at approximately day 42.

• Incidence of clinically significant changes in systolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant increases or decreases in systolic blood pressure, measured in millimeters of mercury (mmHg), will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

  From first dose through treatment and the final study visit at approximately day 42.

• Incidence of clinically significant changes in heart rate (beats per minute) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in heart rate, measured in beats per minute from 12-lead ECG recordings, will be assessed to evaluate the cardiac safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

  Baseline through treatment and the final study visit at approximately day 42.

• Incidence of abnormalities in hematology parameters as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant abnormalities in hematology parameters (e.g., hemoglobin, hematocrit, red blood cell count, white blood cell count, platelet count) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

  Baseline through the end of the study at approximately Day 42.

• Incidence of abnormalities in coagulation parameters as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant abnormalities in coagulation parameters (e.g., PT, aPTT, INR) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

  Baseline through the end of the study at approximately Day 42.

• Incidence of abnormalities in urinalysis parameters as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant abnormalities in urinalysis parameters (e.g., specific gravity, protein, glucose, blood, leukocytes) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

  Baseline through the end of the study at approximately Day 42.

• Incidence of clinically significant changes in diastolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant increases or decreases in diastolic blood pressure, measured in millimeters of mercury (mmHg), will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in heart rate as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in heart rate (beats per minute) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in respiratory rate as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in respiratory rate (breaths per minute) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in body temperature as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in body temperature (°C) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in RR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in RR interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate the cardiac safety and tolerability of ENV-294.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in PR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in PR interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac conduction safety of ENV-294.

  Baseline through the end of the study at approximately Day 42.

• Incidence of clinically significant changes in QRS duration (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in QRS duration, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac conduction safety of ENV-294.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in QT interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in QT interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac repolarization safety of ENV-294.

  Baseline through treatment and the final study visit (approximately Day 42).

• Incidence of clinically significant changes in QTc Bazett (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in QTc Bazett (QT corrected for heart rate using Bazett's formula), measured in milliseconds (ms), will be assessed to evaluate cardiac safety of ENV-294.

  Baseline through treatment and the final study visit (approximately Day 42)

• Incidence of clinically significant changes in QTc Fridericia (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

  The number of participants with clinically significant changes in QTc Fridericia (QT corrected for heart rate using Fridericia's formula), measured in milliseconds (ms), will be assessed to evaluate cardiac safety of ENV-294.

  From enrollment through treatment and the final study visit (approximately Day 42)

Secondary Outcomes (3)

• Maximum observed plasma concentration (Cmax) of ENV-294

  Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

• Time to reach maximum plasma concentration (Tmax) of ENV-294

  Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

• Area under the plasma concentration-time curve from time zero to 24 hours (AUC₀-₂₄h) of ENV-294

  Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

Study Arms (1)

Open-label with once per day dosing

EXPERIMENTAL

Drug: ENV-294 Capsule

Interventions

ENV-294 Capsule DRUG

ENV-294 formulated as 200mg capsules for oral administration will be used for this study.

Open-label with once per day dosing

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be male or female participants who are 18 to 75 years of age
• Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to the first study visit
• Have a history of inadequate response or intolerance to topical corticosteroids or other topical treatments for used atopic dermatitis
• Have moderate-to-severe atopic dermatitis, at the first two study visits
• Use an emollient (except those containing urea) daily for at least 1 week prior to the first study visit and throughout the study

You may not qualify if:

• Have any uncontrolled current or recurrent concomitant illness (eg, hepatitis B surface antigen, hepatitis C virus, or other condition) that could affect the study drug, clinical or laboratory assessments, or could impact participant safety.
• Are using any medication (prescription or over-the-counter) that may interfere with the study product safety evaluations within 14-days prior to the second study visit.
• Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response.

Sponsors & Collaborators

• Enveda Therapeutics: lead

Study Sites (5)

Center for Dermatology Clinical Research, Inc.

Fremont, California, 94538, United States

Location

Skin Sciences, PLLC

Louisville, Kentucky, 40217, United States

Location

J & S Studies

College Station, Texas, 77845, United States

Location

Texas Dermatology and Laser Specialists

San Antonio, Texas, 78218, United States

Location

Virginia Dermatology & Skin Cancer Center

Norfolk, Virginia, 23502, United States

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2025
• First Posted: January 13, 2026
• Study Start: September 10, 2025
• Primary Completion: January 13, 2026
• Study Completion: January 13, 2026
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

US (5)